united scientific group presents virtual series of cancer ... · title: cancer evolution under...

Immunotherapy in Cancer

October, 26, 2020

Jason D. Marshall, Leidos Biomedical Research, Inc., NCI Campus at Frederick, MD

Title: Performance Optimization of a Novel HPV VLP Vaccine in Mice with Novel Adjuvants

Joseph Markowitz, Moffit Cancer Center, FL

Title: Duality of NO in Melanoma

Yan Leyfman, Penn State College of Medicine, PA

Title: Finetune Your CARs: Building the Next Generation of Anti-Cancer Therapies

Shannon Lauberth, University of California at San Diego, CA, USA

Title: Title to be updated

Joost J. Oppenheim, NIH/NCI, MD, USA

Title: Oncolytic Reagents may also Enhance Anti-Tumor Immunity by Inducing MyD88-dependent Maturation of Dendritic Cells

Wayne Godfrey, Vice President of Clinical Development at IGM Bioscience

Title: A Novel Approach to Engineering Antibody Based Immunotherapy

Jerry W. Shay, UT Southwestern Medical Center, Dallas, Texas

Title: Telomere Stress Potentiates STING-Dependent Anti-Tumor Immunity

Guido Kroemer, Gustave Roussy Comprehensive Cancer Center, INSERM, France

Title: Overcoming a Frequent Inborn Immune Defect in Breast Cancer Therapy

William Hearl, Ph.D. CEO, Immunomic Therapeutics, MD

Title: To be Updated

Brian Francica, Tempest Therapeutics, CA

Title: Dual Antagonism of Prostaglandin Receptors EP2 and EP4 by TPST-1495 Suppresses Tumor Growth and Stimulates Antitumor Immunity

Eduardo Davila, University of Colorado CU Comprehensive Cancer Center, CO

Title: Novel Gene Platforms to Maintain the Persistence and Antitumor Activity of TIL-, CAR-, and DC-Based Therapies

Pooja Jain, Drexel University College of Medicine, Philadelphia, PA

Title: The MAPK/ERK-regulated MEF-2 isoforms as potential new target(s) for HTLV-1 induced Adult T-cell leukemia/lymphoma (ATLL)

Jing H. Wang, University of Colorado Anschutz Medical Campus, CO

Title: MHC Class-I Independent Activation of Virtual-Memory CD8 T Cells Induced by Chemotherapeutic Agent-Treated Cancer Cells

Tel: +1 469-854-2280/81Email: cancer.therapy@uniscigroup.org; contact@ichemmeetings.com

Twitter: @KK_usgcancer

United Scientific Group

A non-profit organization

United Scientific Group Presents

Virtual Series of Cancer R&D & ICHEM-2020

Session Speakers

Scott K. Durum, NCI/CCR, NIH, MD, USA

Title: Title to be updated

Lauren V. Wood, Chief Medical Officer, PDS Biotechnology, NJ

Title: Versamune (R-D0TAP): a Transformative Cationic Lipid Nanoparticle Technology Associated with Type I Interferon Specific Activation and Generation of Antibody, CD8 and CD4 T Cell Responses to Recombinant Proteins and Peptide Tumor Antigens